![Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021.](https://imagenes.elpais.com/resizer/v2/HBZN7TZVTVJSV3LAA4HEEPEERY.jpg?auth=15f37280fbe8d72ddfb86f6181a5aea13b7702b3d5495d9baec80e2439925f29&width=414&height=311&smart=true)
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
Karuna’s top asset is KarXT, an experimental antipsychotic with a promising novel mechanism. It’s currently being reviewed by the USFDA for treatment of schizophrenia in adults